Diagnostics-World
Twitter   LinkedIn Facebookinstagram RSS  
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • Post a Press Release
    • View Press Releases
    • Submit a Story
    • Reprint Articles
  • Advertise
    • Media Kit
    • Digital Advertising Opportunities
    • Lead Generation
    • Whitepapers
    • Webinars
    • Podcasts
    • Editorial Calendar
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside Ebooks
  • Events
    • Webinars
    • Industry Events
    • Dx Conferences
    • Tri-Conference
    • Next Generation Dx
    • Dx Innovation Summit
  • About
    • Editorial Profile
    • Editorial Calendar
    • Contact
  • Next Generation Dx Summit
 
  • New AI Tool Uses Gene Sequencing Data To Predict Formation Site Of Cancer

    Diagnostics World | Researchers at Dana-Farber Cancer Institute and Massachusetts Institute of Technology have developed a new tool, based on artificial intelligence, that predicts the likely site of formation for cancer of unknown primary (CUP) tumors.

    Oct 31, 2023
  • Mayo Clinic And Oxford Nanopore Partner Up, Walgreens Teams Up With Cardiovascular Research Foundation, Cancer Research Horizons And Genialis Data Share

    Diagnostics World | Mayo Clinic and Oxford Nanopore Technologies teams up in a multi-year joint development collaboration to help improve patient care, including some of the hardest-to-characterize conditions and sequencing DNA; Walgreens and the Cardiovascular Research Foundation (CRF) collaborates to drive the PREVUE-VALVE study, which will help pave the way for the development of new therapies and tools for VHD detection and diagnosis; Genialis announces a new data-sharing collaboration with Cancer Research Horizons to better predict responses to KRAS inhibitors, immunotherapies, and other emerging classes of therapeutics; and more.

    Oct 26, 2023
  • Follow the Money: Harbinger Health’s Massive Cancer-Screening Platform Study, New IVD Funding for Oxford Nanopore In Vivo Reprogramming Therapies, HHS Grant For Substance Abuse, HIV Treatment

    Diagnostics World | bioMérieux further invests in Oxford Nanopore to expand in vitro diagnostics production; Harbinger Health trials blood-based cancer screening platform; HHS funds behavioral health services and HIV prevention for underserved populations; and more.

    Oct 25, 2023
  • «
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50 (current)
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Twitter Icon LinkedIn Icon Facebook Icon

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy